Magazine Article | July 5, 2018

Why A Spin-off Is A Win-Win For Big Pharma And Startups

Source: Life Science Leader

By Gail Dutton, Contributing Writer
Follow Me On Twitter @GailLdutton

When Viela Bio spun out of MedImmune in March, it started with six assets — three in clinical trials and three in preclinical development — putting it ahead of most startups and many spin-offs. “Other spin-offs often are developing assets that have been shelved for various reasons or that have been deprioritized,” Bing Yao, Ph.D., CEO, notes. “But for Viela Bio, this is a continuation of the programs, not a handoff.”

Ensuring projects remain on track during the transition is Yao’s highest priority. Hiring the core team that developed these molecules at MedImmune was the best way to do that, along with contracting some transition work back to MedImmune. As a result, Viela Bio’s development team was up to speed from day one.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader